IIFL Securities Stock Market Watch Today: Buy Piramal Pharma - March 28

IIFL Securities has issued a buy recommendation for Piramal Pharma, setting a target price of Rs. 133. This represents an upside potential of around 3.4% from the current market price of Rs. 128.6. The bullish call is based on the company's strong fundamentals, including its robust product portfolio, leadership in the domestic critical care market, and growing presence in international markets. Investors who believe in the long-term growth prospects of the company may consider this recommendation for potential gains.

About Piramal Pharma:

Piramal Pharma Limited (PPL) is a leading global pharmaceutical company headquartered in Mumbai, India. It focuses on various therapeutic segments, including respiratory, critical care, pain management, anti-infectives, central nervous system (CNS), and others. PPL has a robust product portfolio with a presence in over 100 countries worldwide. The company's R&D capabilities and strong pipeline of generic and innovative products contribute to its growth. PPL is committed to providing accessible and affordable medicines to patients globally. Additionally, it has a presence in the consumer healthcare segment through OTC products and branded generics.

52 Week Price Trend:

Piramal Pharma, with a current market price of Rs 128.6, has witnessed significant fluctuations over the past year. Its 52-week high of Rs 149 reflects a potential upside of 16%, while its 52-week low of Rs 61.62 suggests a possible downside risk of approximately 50%. This wide range of movement indicates the company's sensitivity to market dynamics and the potential for volatility in its share price. Investors considering Piramal Pharma should carefully evaluate the company's financial performance, competitive landscape, and overall market conditions before making any investment decisions.

Stratzy's MOST Analysis:

PPLPHARMA has received a BB- rating from Stratzy's MOST framework, indicating medium fundamental risks. This rating is based on an assessment of the company's management, outlook, safety, and trend. While the company's management and safety aspects may be satisfactory, its outlook and trend may have some areas for improvement. This rating provides investors with valuable insights into the company's overall financial health and stability, helping them make informed investment decisions.

Fundamental and Technical information provided in this blog were last updated on 28 Mar, 2024

Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.